
Investments
29Portfolio Exits
17Funds
5Service Providers
1About Leerink Partners
Leerink Partners is an investment bank with a focus on serving innovation-driven and growth-minded companies in the healthcare and life science sectors. The company offers a broad suite of financial solutions including M&A advisory, equity and debt capital markets, proprietary research, and comprehensive sales and trading capabilities. It primarily serves the healthcare industry, including sectors such as biopharma, digital health and healthtech, healthcare services, medical technology, and tools and diagnostics. The company was founded in 1995 and is based in Boston, Massachusetts.
Latest Leerink Partners News
Dec 7, 2023
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares December 07, 2023 at 07:01 am EST Share CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about December 11, 2023, subject to customary closing conditions. J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering. Mizuho and Truist Securities are acting as book-runners and H.C. Wainwright & Co. and Raymond James are acting as co-managers for the offering. The offering is being made only by means of a prospectus and related prospectus supplement forming part of a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”). The preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on December 6, 2023. The final prospectus supplement and the accompanying prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; or from Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding the closing of the public offering of ordinary shares. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected and Wave cautions investors not to place undue reliance on the forward-looking statements in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. There can be no assurance that Wave will be able to complete the public offering on the anticipated terms, or at all. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s preliminary prospectus supplement related to the proposed offering filed with the SEC on December 6, 2023 and Wave’s most recent Annual Report on Form 10-K filed with the SEC, as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. Investor Contact: Wave Life Sciences Ltd. is a clinical-stage genetic medicines company. The Company is engaged in developing medicines across multiple therapeutic modalities using PRISM, its proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. The Company's ribonucleic acid (RNA)-targeting oligonucleotides is designed to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. Its lead programs are designed to treat genetic diseases, including those in muscle, including Duchenne muscular dystrophy (DMD); liver, including alpha-1 antitrypsin deficiency (AATD); and the central nervous system (CNS), including Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These programs include WVE-N531, WVE-006, WVE-003, and WVE-004. Sector
Leerink Partners Investments
29 Investments
Leerink Partners has made 29 investments. Their latest investment was in Odyssey Therapeutics as part of their Series C on December 12, 2023.

Leerink Partners Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
12/5/2023 | Series C | Odyssey Therapeutics | $101M | Yes | AB Magnitude Ventures, Alexandria Venture Investments, Ascenta Capital, BlackMars Capital, Catalio Capital Management, Colt Ventures, Creacion Ventures, Fidelity Investments, Foresite Capital, General Catalyst, Global BioAccess Fund, HBM Healthcare Investments, Healthcare Innovation, KB Investment, OrbiMed Advisors, Racing Beach Ventures, SR One, T. Rowe Price, Undisclosed Investors, Walleye Capital, and Woodline Partners | 6 |
6/15/2021 | Series B | Umoja Biopharma | $210M | Yes | 13 | |
12/14/2020 | Series B | LocanaBio | $100M | Yes | 28 | |
8/4/2020 | Series C | |||||
4/6/2020 | Series E |
Date | 12/5/2023 | 6/15/2021 | 12/14/2020 | 8/4/2020 | 4/6/2020 |
---|---|---|---|---|---|
Round | Series C | Series B | Series B | Series C | Series E |
Company | Odyssey Therapeutics | Umoja Biopharma | LocanaBio | ||
Amount | $101M | $210M | $100M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | AB Magnitude Ventures, Alexandria Venture Investments, Ascenta Capital, BlackMars Capital, Catalio Capital Management, Colt Ventures, Creacion Ventures, Fidelity Investments, Foresite Capital, General Catalyst, Global BioAccess Fund, HBM Healthcare Investments, Healthcare Innovation, KB Investment, OrbiMed Advisors, Racing Beach Ventures, SR One, T. Rowe Price, Undisclosed Investors, Walleye Capital, and Woodline Partners | ||||
Sources | 6 | 13 | 28 |
Leerink Partners Portfolio Exits
17 Portfolio Exits
Leerink Partners has 17 portfolio exits. Their latest portfolio exit was Vera Whole Health on July 01, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
7/1/2021 | Acq - Fin | 2 | |||
3/22/2021 | Acquired | 8 | |||
12/3/2020 | IPO | Public | 11 | ||
Date | 7/1/2021 | 3/22/2021 | 12/3/2020 | ||
---|---|---|---|---|---|
Exit | Acq - Fin | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 8 | 11 |
Leerink Partners Fund History
5 Fund Histories
Leerink Partners has 5 funds, including Leerink Revelation Partners Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
6/12/2018 | Leerink Revelation Partners Fund II | $227M | 1 | ||
9/29/2017 | Health IT Growth Equity Fund I | ||||
7/6/2016 | Leerink Transformation Fund I | ||||
6/11/2015 | LEERINK Revelation Partners | ||||
Massachusetts Innovation Catalyst Fund |
Closing Date | 6/12/2018 | 9/29/2017 | 7/6/2016 | 6/11/2015 | |
---|---|---|---|---|---|
Fund | Leerink Revelation Partners Fund II | Health IT Growth Equity Fund I | Leerink Transformation Fund I | LEERINK Revelation Partners | Massachusetts Innovation Catalyst Fund |
Fund Type | |||||
Status | |||||
Amount | $227M | ||||
Sources | 1 |
Leerink Partners Service Providers
1 Service Provider
Leerink Partners has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acquired | Investment Bank | Financial Advisor |
Service Provider | |
---|---|
Associated Rounds | Acquired |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Leerink Partners Team
22 Team Members
Leerink Partners has 22 team members, including current Chief Executive Officer, Jeffrey A. Leerink.
Loading...